Get the Stockscreener App
20.27
0.44%
-0.09
After Hours:
20.27
Enliven Therapeutics Inc stock is traded at $20.27, with a volume of 589.23K.
It is down -0.44% in the last 24 hours and up +1.00% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$20.36
Open:
$20.46
24h Volume:
589.23K
Relative Volume:
1.14
Market Cap:
$1.20B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-10.72
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-2.78%
1M Performance:
+1.00%
6M Performance:
+0.60%
1Y Performance:
-8.78%
1-Day Range:
$19.92
$20.99
1-Week Range:
$19.92
$21.14
52-Week Range:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.27 | 1.21B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Smart tools for monitoring Enliven Therapeutics Inc.’s price actionEarnings Summary Report & Community Supported Trade Ideas - Newser
Risk vs reward if holding onto Enliven Therapeutics Inc.July 2025 EndofMonth & Safe Capital Growth Tips - Newser
How to interpret RSI for Enliven Therapeutics Inc. stockShare Buyback & Precise Trade Entry Recommendations - Newser
Can Enliven Therapeutics Inc. hit a new high this monthShare Buyback & Detailed Earnings Play Alerts - Newser
Visual trend scoring systems applied to Enliven Therapeutics Inc.GDP Growth & Stepwise Trade Execution Plans - Newser
Visualizing Enliven Therapeutics Inc. stock with heatmapsQuarterly Growth Report & Verified Trade Idea Suggestions - Newser
Can machine learning forecast Enliven Therapeutics Inc. recoveryOptions Play & Real-Time Volume Trigger Notifications - Newser
Using data tools to time your Enliven Therapeutics Inc. exitMarket Movement Recap & Smart Investment Allocation Tips - Newser
Technical signs of recovery in Enliven Therapeutics Inc.Weekly Trade Review & AI Enhanced Market Trend Forecasts - Newser
Enliven Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Decliners & Growth Oriented Trading Recommendations - Newser
Can volume confirm reversal in Enliven Therapeutics Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser
How to build a custom watchlist for Enliven Therapeutics Inc.Oil Prices & Reliable Trade Execution Plans - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityPortfolio Risk Report & High Return Trade Opportunity Guides - Newser
Combining price and volume data for Enliven Therapeutics Inc.Wall Street Watch & Technical Entry and Exit Alerts - Newser
Enliven Therapeutics Inc. Recovery Potential Based on Technical Tools getLinesFromResByArray error: size == 0 - thegnnews.com
Is Enliven Therapeutics Inc. stock risky to hold nowJuly 2025 Market Mood & Detailed Earnings Play Strategies - sundaytimes.kr
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):